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Clinical Trial Registration: Looking Back and Moving Ahead
In 2005, the International Committee of Medical JournalEditors (ICMJE) initiated a policy requiring investigators
to deposit information about trial design into an accepted
clinical trials registry before the onset of patient enrollment
(1). This policy aimed to ensure that information about
the existence and design of clinically directive trials was
publicly available, an ideal that leaders in evidence-based
medicine have advocated for decades (2). The policy pre-
cipitated much angst among research investigators and
sponsors, who feared that registration would be burden-
some and would stifle competition. Yet, the response to
this policy has been overwhelming. The ICMJE promised
to reevaluate the policy in 2 years after implementation.
Here, we summarize that reevaluation, specifically com-
menting on registries that meet the policy requirements,
the types of studies that require registration, and the regis-
tration of trial results. As is always the case, the ICMJE
establishes policy only for the 12 member journals (a de-
tailed description of the ICMJE and its purpose is available
at www.icmje.org), but many other journals have adopted
our initial trial registration recommendations, and we hope
that they will also adopt the modifications discussed in this
update.
The research community has embraced trial registra-
tion. Before the ICMJE policy, ClinicalTrials.gov, the larg-
est trial registry at the time, contained 13 153 trials; this
number climbed to 22 714 one month after the policy
went into effect (3). In April 2007, the registry contained
over 40 000 trials, with more than 200 new trial registra-
tions occurring weekly (Zarin D. Personal communica-
tion). The 4 other registries that meet the ICMJE criteria
have also grown as scores of journals have adopted the
ICMJE clinical trials registration policy. In response to
burgeoning registration, many investigators, sponsors, and
government agencies have asked the ICMJE to recognize
their local registries as databases that meet the policy. For-
tunately, the World Health Organization’s (WHO) Inter-
national Clinical Trial Registry Platform (ICTRP), which
was nascent when the ICMJE began to require trial regis-
tration, has matured rapidly and provides options for those
that desire a wider array of registries. The ICTRP has taken
the first steps toward developing a network of primary and
partner registers that meet WHO-specified criteria (4). Pri-
mary registers are WHO-selected registers managed by
not-for-profit entities that will accept registrations for any
interventional trials, delete duplicate entries from their
own register, and provide data directly to the WHO. Part-
ner registers, which will be more numerous, will include
registers that submit data to primary registers but limit
their own register to trials in a restricted area (such as a
specific disease, company, academic institution, or geo-
graphic region).
The ICMJE strongly supports the WHO’s efforts,
through the ICTRP, to develop a coordinated process for
identifying, gathering, deduplicating, and searching trials
from registries around the world, thus eventually providing
a 1-stop search portal for those seeking information about
clinical trials. In addition to the 5 existing registries, the
ICMJE will now also accept registration in any of the pri-
mary registers that participate in the WHO ICTRP. Be-
cause it is critical that trial registries are independent of
for-profit interests, the ICMJE policy requires registration
in a WHO primary register rather than solely in a partner
register, since for-profit entities manage some partner reg-
isters. As previously, trial registration with missing or un-
informative fields for the minimum data elements is inad-
equate (1).
Initially, the ICMJE required registration of all clini-
cally directive trials, which it defined as “any research
project that prospectively assigns human subjects to inter-
vention or comparison groups to study the cause-and-effect
relationship between a medical intervention and a health
outcome” (1). In May 2005, the ICMJE clarified this def-
inition to exclude preliminary trials designed to study
pharmacokinetics or major unknown toxicity (phase I tri-
als) (5). However, the ICMJE recognizes the potential ben-
efit of having information about preliminary trials in the
public domain, because these studies can guide future re-
search or signal safety concerns. Consequently, the ICMJE
is expanding the definition of the types of trials that must
be registered to include these preliminary trials and adopts
the WHO’s definition of clinical trial: “any research study
that prospectively assigns human participants or groups of
humans to one or more health-related interventions to
evaluate the effects on health outcomes” (4). Health-
related interventions include any intervention used to
modify a biomedical or health-related outcome (for exam-
ple, drugs, surgical procedures, devices, behavioral treat-
ments, dietary interventions, and process-of-care changes).
Health outcomes include any biomedical or health-related
measures obtained in patients or participants, including
pharmacokinetic measures and adverse events. As previ-
ously, purely observational studies (those in which the as-
signment of the medical intervention is not at the discre-
tion of the investigator) will not require registration. The
ICMJE member journals will start to implement the ex-
panded definition of clinically directive trials for all trials
that begin enrollment on or after 1 July 2008. Those who
are uncertain whether their trial meets the expanded
ICMJE definition should err on the side of registration if
they wish to seek publication in an ICMJE journal.
Over the time during which registration of trial meth-
ods has become common practice, several forces have be-
gun advocating for registration of trial results. We recog-
nize that the climate for results registration will probably
change dramatically and unpredictably over coming years.
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For the present, the ICMJE will not consider results posted
in the same primary clinical trials register in which the
initial registration resides as previous publication if the re-
sults are presented in the form of a brief, structured (500
words) abstract or table. The ICMJE favors a standard
abstract format for results reporting, and the CONSORT
(Consolidated Standards for the Reporting of Trials)
group’s forthcoming guidelines for abstracts related to tri-
als may be one such option. The ICMJE believes that par-
ties interested in results registration should consider requir-
ing the deposition of such an abstract in the registry 24
months after closure of data collection if results are not
published in a peer-reviewed venue by that time. The reg-
istered abstract should either cite any related full, peer-
reviewed publications or include a statement that indicates
that the report has not yet been published in a peer-re-
viewed journal. Researchers should be aware that editors
may consider more detailed deposition of trial results in
publicly available registries to be prior publication. When
submitting a paper, authors should fully disclose to editors
all posting in registries of results of the same or closely
related work.
Three years ago, trials registration was the exception;
now it is the rule. Registration facilitates the dissemination
of information among clinicians, researchers, and patients,
and it helps to assure trial participants that the information
that accrues as a result of their altruism will become part of
the public record. The WHO’s global efforts towards com-
prehensive trials registration and the ICMJE’s require-
ments for registration aim to increase public trust in med-
ical science.
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Key Summary Points
In addition to accepting registration in any of the 5 exist-
ing registries, the ICMJE will accept registration of clinical
trials in any of the primary registers that participate in the
WHO ICTRP. Registration in a partner register only is in-
sufficient.
The ICMJE will begin to implement the WHO definition of
clinical trials for all trials that begin enrollment on or after
1 July 2008. This definition states that a clinical trial is “any
research study that prospectively assigns human partici-
pants or groups of humans to one or more health-related
interventions to evaluate the effects on health outcomes.”
The ICMJE will not consider results posted in the same
clinical trials registry in which the primary registration re-
sides to be previous publication if the results are presented
in the form of a brief, structured (500 words) abstract or
table.
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